PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia

Leukemia

Volumn 31, Issue 3, 2017, Pages 738-743

  Goltz, D ^a   Gevensleben, H ^a   Grunen S ^a   Dietrich, J ^a   Kristiansen, G ^a   Landsberg, J ^a   Dietrich, D ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC INFLAMMATION; COMPARATIVE STUDY; DNA METHYLATION; HELPER CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LETTER; LEUKEMIA REMISSION; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; FEMALE; GENETIC EPIGENESIS; GENETICS; INFLAMMATION; MALE; METHYLATION; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE;

B7-H1 ANTIGEN; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LEUKEMIA, MYELOID, ACUTE; MALE; METHYLATION; MIDDLE AGED; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES; UP-REGULATION;

EID: 85001052421     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.328     Document Type: Letter

References (15)

1. Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol 2013; 162: 509-516.
2. Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol 2016; 103: 62-77.
3. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010; 116: 2484-2493.
4. Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol 2013; 43: 747-757.
5. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTLmediated lysis. Blood 2004; 104: 2124-2133.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
7. Orskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015; 6: 9612-9626.
8. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014; 28: 1280-1288.
9. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 2016; 27: 409-416.
10. Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011; 35: 400-412.
11. Cribbs AP, Kennedy A, Penn H, Read JE, Amjadi P, Green P, et al. Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2, 3-dioxygenase pathway. Arthritis Rheumatol 2014; 66: 2344-2354.
12. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
13. Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003; 101: 202-209.
14. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
15. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.